The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onchocerciasis.T...
Main Authors: | Fidelis Cho-Ngwa, Jing Liu, Sara Lustigman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-08-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC2927424?pdf=render |
Similar Items
-
Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
by: Parakkal Jovvian George, et al.
Published: (2019-09-01) -
Patent infections with soil-transmitted helminths and Schistosoma mansoni are not associated with increased prevalence of antibodies to the Onchocerca volvulus peptide epitopes OvMP-1 and OvMP-23
by: Johnny Vlaminck, et al.
Published: (2019-01-01) -
Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of Onchocerca volvulus.
by: Robert Adamu Shey, et al.
Published: (2018-01-01) -
Ivermectin resistance in Onchocerca volvulus: toward a genetic basis.
by: Sara Lustigman, et al.
Published: (2007-08-01) -
Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein.
by: Ferdinand Ngale Njume, et al.
Published: (2019-07-01)